Mexico Recently appointed CEO and president for Pfizer Mexico, Constanza Losada, outlines the exciting challenge of taking on leadership for such an important affiliate during the COVID-19 pandemic and how Pfizer is contributing to the fight against the virus. Losada also outlines her strategy for ensuring patient access to Pfizer’s innovative…
Coronavirus Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University. The worldwide race against the clock to develop an effective coronavirus vaccine has been underway since early 2020. University research teams, public and private…
Coronavirus At the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, Pfizer chairman and CEO Dr Albert Bourla outlined why the US firm had decided to take a different tack to that of its rivals in developing a vaccine using the innovative but as yet unproven Messenger RNA (mRNA) technology…
Europe The EFPIA’s Nathalie Moll gives an insight into the work underway across the European pharmaceutical industry to battle COVID-19 in terms of supporting organisations on the ground, ensuring the supply of medicines, and working on the research and development of treatments, vaccines, and diagnostics. Moll also outlines the vital importance…
Korea Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical trials around COVID-19 treatments are progressing in Korea, the pandemic’s effect on trials for medicines in other indications, and how…
Coronavirus During the 30 April IFPMA virtual media briefing on COVID-19 treatments, key global executives pushed beyond catchy headlines to discuss the current reality of COVID-19 R&D efforts. MSD (Merck & Co. in the US and Canada) executive vice president and chief patient officer Julie Gerberding drew upon her valuable…
Hong Kong Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy to develop their brand in South East Asia, the changes he foresees for the industry post the COVID-19 pandemic, and…
Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.* Last week, high-level representatives from seven companies…
China Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on the Hong Kong Stock Exchange and their first product, toripalimab, being the first anti-PD-1 monoclonal antibody self-developed by a Chinese…
Korea Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing clinical trials, and the complementarity of oncolytic virus with other gene therapies such as CAR-T. Oncolytic virus is not…
Belgium Marijke Eyssen of the Belgian Health Care Knowledge Centre (KCE) introduces the institution’s mission, core values, how it chooses areas of research, and the crucial work the KCE does in non-industry clinical trials. High scientific quality is also really important to us, as well as transparency in our reporting.…
Belgium Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and how the importance of the Society’s network of international partnerships. We need to have everyone on board, in order…
See our Cookie Privacy Policy Here